A recent randomized controlled trial involving 71 patients with type 2 diabetes showed that LCD does not adversely affect endothelial function and markers of inflammations as interleukin-6 (IL-6) or high-sensitivity C-reactive protein (hsCRP), demonstrating that this dietary approach does not increase the risk of cardiovascular disease [72]. The gene discussed is IL6; the disease is type 2 diabetes mellitus.